What is Poxel?
Poxel operates at the intersection of advanced medical research and pharmaceutical development, focusing on innovative treatments for serious chronic conditions. The company's core competency lies in its robust pipeline, which targets liver and rare metabolic disorders—areas of significant unmet medical need. Beyond its internal R&D efforts, Poxel maintains a diversified revenue model, bolstered by royalty-related income from a partnered diabetes therapy currently commercialized in Japan. This dual-track strategy of internal innovation and external commercial partnerships provides a stable foundation for its long-term growth objectives in the global biopharma sector.
How much funding has Poxel raised?
Poxel has raised a total of $71.4M across 6 funding rounds:
Series A
$21M
Series B
$13.5M
Share Placement
$19.4M
Unspecified
$7M
Debt
$6.1M
Other Financing Round
$4.3M
Series A (2010): $21M with participation from Edmond de Rothschild
Series B (2014): $13.5M, investors not publicly disclosed
Share Placement (2020): $19.4M supported by Undisclosed
Unspecified (2020): $7M featuring BNP Paribas and Bpifrance
Debt (2022): $6.1M backed by IRIS
Other Financing Round (2026): $4.3M with participation from IPF Partners
Key Investors in Poxel
Edmond de Rothschild
Edmond de Rothschild, founded in 1923 and headquartered in France, is an investment banking firm offering various financial services and solutions.
BNP Paribas
BNP Paribas is a leading international banking group headquartered in Paris, France, and is widely regarded as one of Europe’s largest and most diversified financial institutions.
IPF Partners
IPF Partners is a prominent alternative financing provider focused exclusively on the healthcare sector, offering tailored debt and equity financing solutions.
What's next for Poxel?
With the successful closure of this major strategic investment, Poxel is poised to advance its clinical-stage assets through critical development milestones. The company's strategic roadmap likely involves intensifying its focus on late-stage clinical trials and expanding its therapeutic footprint in the metabolic space. As the firm navigates the complexities of drug development, the infusion of capital will be instrumental in supporting regulatory engagements and potential commercialization efforts. Investors and industry stakeholders will be closely monitoring the progression of its lead candidates, as the company seeks to translate its scientific breakthroughs into tangible patient outcomes and sustained shareholder value.
See full Poxel company page
